The molecular interactions between hosts, vectors and pathogens drive the etiology of infectious diseases. At first sight, the Guillain-Barré and Alpha-Gal syndromes have quite different etiologies but, as proposed here, a closer look into the immune response to galactose-containing oligosaccharide structures that characterizes these two diseases reveals striking commonalities. In this Opinion paper, we address the main molecular drivers of two apparently unrelated diseases, and how the characterization of the immune response and immunological tolerance would advance the control and prevention of these diseases.
Immune boosters – do we need them?
Lourdes MATEOS-HERNÁNDEZ, PostDoc Position, BSc, MSc, PhD, Agence Nationale de Sécurité Sanitaire de l'Alimentation, de l'Environnement et du Travail, Maisons-Alfort, ANSES, Maisons-Alfort Laboratory for Animal Health
Lourdes MATEOS-HERNÁNDEZ, PostDoc Position, BSc, MSc, PhD, Agence Nationale de Sécurité Sanitaire de l'Alimentation, de l'Environnement et du Travail, Maisons-Alfort, ANSES, Maisons-Alfort Laboratory for Animal Health
Guillain–Barré syndrome: a century of progress
Guillain–Barré syndrome in Asia Journal of Neurology, Neurosurgery & Psychiatry
PDF) Novel Case Presentation of Abulia After Lone Star Tick Bite As Evidenced by Raised Titers of Alpha-Gal Specific IgM Immunoglobulin and a Possibility of Alpha-Gal Driven Hypothalamic Dysfunction As the Pathomechanism
Frontiers Intensive Care and Treatment of Severe Guillain–Barré Syndrome
Diagnosis and treatment of the alpha-Gal syndrome
PDF) Novel Case Presentation of Abulia After Lone Star Tick Bite As Evidenced by Raised Titers of Alpha-Gal Specific IgM Immunoglobulin and a Possibility of Alpha-Gal Driven Hypothalamic Dysfunction As the Pathomechanism
The glycobiology of microbial infectious disease - ScienceDirect
Diagnosis and treatment of the alpha-Gal syndrome
Frontiers Biosynthesis of α-Gal Epitopes (Galα1-3Galβ1-4GlcNAc-R) and Their Unique Potential in Future α-Gal Therapies